The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are associated with improved long-term survival compared with wedge resection, ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Korea: A recent study published in the Radiology Journal has highlighted the significant role of obesity and skeletal muscle ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

THE proportion of people diagnosed with lung cancer who’ve never smoked is increasing, the World Health Organization (WHO) ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

The five-year relative survival rate of small cell lung cancer—the odds that a cancer patient will live another five years compared to a non-patient—ranges from 7% to 30% depending on the ...